Intelligence artificielle dans l’industrie pharmaceutique : gouvernance, qualité et enjeux réglementaires
Annales Pharmaceutiques Françaises · 2026-07
DOI: 10.1016/j.pharma.2026.06.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annales Pharmaceutiques Françaises, 2026-07. Verfasst von Jean-Marie Ouedraogo. Beteiligte Einrichtung: Euromed University of Fez, Euromed Research Center, 30000 Fez, Maroc. Electronic address: j.ouedraogo@ueuromed.org. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE Artificial intelligence (AI) is progressively transforming the pharmaceutical industry by impacting manufacturing, quality assurance, regulatory affairs, supply chain management, and governance of industrial systems. The objective of this review is to provide a critical synthesis of the applications, limitations, and regulatory challenges associated with the integration of AI into regulated pharmaceutical environments. METHODOLOGY This narrative review is based on a corpus of more than forty recent academic publications, institutional reports, and regulatory documents covering pharmaceutical manufacturing, Good Manufacturing Practices (GMP), quality assurance, regulatory affairs, supply chain management, data governance, organizational adoption, and sustainability. RESULTS AI contributes to process optimization, predictive maintenance, real-time quality control, document automation, regulatory decision support, and improved supply chain performance. It also promotes the emergence of more connected and adaptive production models within the framework of Pharma 4.0. However, these benefits remain highly dependent on data quality and interoperability, model validation, system explainability, cybersecurity, GMP constraints, governance requirements, and the control of generative AI use in regulated environments. CONCLUSION AI represents a major driver of transformation in the pharmaceutical industry, but its value depends on its integration into robust industrial, organizational, and regulatory frameworks. The development of pharmaceutically credible AI requires systems that are validatable, governable, auditable, and compatible with the trust requirements inherent to healthcare activities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Euromed University of Fez, Euromed Research Center, 30000 Fez, Maroc. Electronic address: j.ouedraogo@ueuromed.org.
Zitieren
APA
Ouedraogo, J. M. (2026). Intelligence artificielle dans l’industrie pharmaceutique : gouvernance, qualité et enjeux réglementaires. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2026.06.011
Vancouver
Ouedraogo JM. Intelligence artificielle dans l’industrie pharmaceutique : gouvernance, qualité et enjeux réglementaires. Annales Pharmaceutiques Françaises. 2026. doi:10.1016/j.pharma.2026.06.011
BibTeX
@article{Ouedraogo2026,
author = {Ouedraogo, Jean-Marie},
title = {Intelligence artificielle dans l’industrie pharmaceutique : gouvernance, qualité et enjeux réglementaires},
journal = {Annales Pharmaceutiques Françaises},
year = {2026},
doi = {10.1016/j.pharma.2026.06.011}
}
EUVIMED